Abstract

Objective: To develop a systematic set of German cost data in rheumatoid arthritis (RA) based solely on valid healthcare payer’s cost data sources. Methods: Retrospectively one year cost data of...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide in rheumatoid arthritis in Germany
Matthias Schneider ... Henning Zeidler
PharmacoEconomics | VOL. 23
Matthias Schneider, et. al.Matthias Schneider ... Henning Zeidler
01 Apr 2005
Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards.
J�Rg Ruof ... Thomas Mittendorf
The European journal of health economics : HEPAC : health economics in prevention and care | VOL. 5
J�Rg Ruof, et. al.J�Rg Ruof ... Thomas Mittendorf
01 Feb 2004
Modelling cost effectiveness and cost utility of sequential DMARD therapy including leflunomide for rheumatoid arthritis in Germany
Christoph Straub ... Erika Gromnica-Ihle
PharmacoEconomics | VOL. 23
Christoph Straub, et. al.Christoph Straub ... Erika Gromnica-Ihle
01 Apr 2005
Depression risk in patients with late-onset rheumatoid arthritis in Germany.
Karel Kostev ... Julia Drosselmeyer
Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation | VOL. 26
Karel Kostev, et. al.Karel Kostev ... Julia Drosselmeyer
08 Aug 2016
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers